EUVIMEDEUVIMED entdecken
Crossref

Genomic and transcriptomic insights into the precision treatment of pulmonary enteric adenocarcinoma

Yuan Liu, Tao Lu, Mingming Yuan, Rongrong Chen, Junliang Lu, Hanping Wang, Zhiyong Wu, Yingyi Wang

Lung Cancer · 2023-05 · 179 · 107169

DOI: 10.1016/j.lungcan.2023.03.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lung Cancer, 2023-05. Verfasst von Yuan Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing,…. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Beijing Municipal Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pulmonary enteric adenocarcinoma (PEAC) is a rare subtype of lung adenocarcinoma. More investigations about precision therapy in PEAC were required to improve the prognosis. METHODS: Twenty-four patients with PEAC were enrolled in this study. Tumor tissue samples were available from 17 patients for both DNA and RNA based next-generation sequencing, PD-L1 IHC staining and PCR-based microsatellite instability (MSI) analysis. RESULTS: TP53 (70.6%) and KRAS (47.1%) were the most frequently mutated genes in PEAC. For KRAS mutations, the prevalence of G12D (37.5%) and G12V (37.5%) was higher than G12A (12.5%) and G12C (12.5%). Actionable mutations in receptor tyrosine kinase (including one EGFR and two ALK mutations), PI3K/mTOR, RAS/RAF/MEK, homologous recombination repair (HRR) and cell cycle signaling pathways were identified in 94.1% of patients with PEAC. While PD-L1 expression was observed in 17.6% (3/17) patients, no MSI-H patients were identified. Transcriptomic data showed that two patients with positive PD-L1 expression had relatively high immune infiltration. In addition, prolonged survival was obtained with the treatment of osimertinib, ensartinib, and immunotherapy combined with chemotherapy in two EGFR-mutated, one ALK-rearranged, and one PD-L1 expressed patients, respectively. CONCLUSION: PEAC is a disease of genetic heterogeneity. The administration of EGFR and ALK inhibitors was effective in patients with PEAC. PD-L1 expression and KRAS mutation type may be used as predictive biomarkers for immunotherapy in PEAC. This study provided both theoretical basis and clinical evidence for PEAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungHumansB7-H1 AntigenTranscriptomeProto-Oncogene Proteins p21(ras)GenomicsErbB ReceptorsReceptor Protein-Tyrosine KinasesMutationBiomarkers, Tumor

Stichwörter der Autor:innen

ImmunotherapyNext-generation sequencingPredictive biomarkerPulmonary enteric adenocarcinomaTargeted therapy

Substanzen

B7-H1 AntigenProto-Oncogene Proteins p21(ras)ErbB ReceptorsReceptor Protein-Tyrosine KinasesBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Geneplus-Beijing, Beijing, China.
  • Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Medical Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: wangyingyi@pumch.cn.

Förderung

  • Beijing Municipal Science and Technology Commission

Zitieren

APA

Liu, Y., Lu, T., Yuan, M., Chen, R., Lu, J., Wang, H., Wu, Z., & Wang, Y. (2023). Genomic and transcriptomic insights into the precision treatment of pulmonary enteric adenocarcinoma. Lung Cancer, 179, 107169. https://doi.org/10.1016/j.lungcan.2023.03.005

Vancouver

Liu Y, Lu T, Yuan M, Chen R, Lu J, Wang H, et al. Genomic and transcriptomic insights into the precision treatment of pulmonary enteric adenocarcinoma. Lung Cancer. 2023;179:107169. doi:10.1016/j.lungcan.2023.03.005

BibTeX
@article{Liu2023,
  author = {Liu, Yuan and Lu, Tao and Yuan, Mingming and Chen, Rongrong and Lu, Junliang and Wang, Hanping and Wu, Zhiyong and Wang, Yingyi},
  title = {Genomic and transcriptomic insights into the precision treatment of pulmonary enteric adenocarcinoma},
  journal = {Lung Cancer},
  year = {2023},
  volume = {179},
  pages = {107169},
  doi = {10.1016/j.lungcan.2023.03.005}
}
Kostenlos starten →